What Are The Absolute And Relative Contraindications Clinics Must Screen For Before Conducting Er:yag Or Co2 Fractional Laser Resurfacing? Key Safety Criteria

Clinics should first exclude conditions that make healing unsafe or post-treatment care unreliable. For fractional Er:YAG or CO₂ resurfacing, the principal absolute exclusions are active treatment-area infection, significant connective-tissue disease such as systemic lupus erythematosus or scleroderma, active keloid formation, recent systemic isotretinoin use under the clinic’s required interval, and inability to follow strict wound-care and sun-protection instructions. Relative risks—including HSV history, darker phototype, smoking, diabetes, prior scarring, and active acne—require treatment modification, prophylaxis, delay, or a test patch rather than automatic rejection.

The key distinction is whether the patient cannot safely heal or cannot safely follow aftercare. Absolute contraindications generally mean “do not treat”; relative contraindications mean “treat only after risk reduction, conservative settings, specialist input, or a localized test patch.”

What Clinics Must Screen Before Resurfacing

Confirm the procedure and treatment depth

Fractional devices do not carry identical risks. Fractional ablative CO₂ and Er:YAG create columns of vaporized or thermally injured tissue, while non-ablative fractional devices generally produce less disruption.

The deeper and more extensive the treatment, the more important wound healing, adnexal structures, infection risk, pigment risk, and eyelid mechanics become. A contraindication that may be unacceptable for aggressive full-field resurfacing may be manageable with a conservative fractional protocol.

Document baseline risk factors

The screening history should include:

Prior keloids or hypertrophic scars
Herpes simplex history
Autoimmune or connective-tissue disease
Diabetes, immune suppression, and vascular disease
Smoking or nicotine use
Current and recent medications, especially isotretinoin and photosensitizers
Prior radiation, deep chemical peels, dermabrasion, or extensive electrolysis
Skin phototype and history of post-inflammatory hyperpigmentation
Pregnancy or breastfeeding status
Ability to perform wound care and strict sun protection
Expectations regarding downtime and the achievable result

A focused examination should identify infection, active inflammatory disease, impaired skin appendages, eyelid laxity, and the condition of the proposed treatment area.

Absolute Contraindications

Active infection in the treatment area

Active bacterial, viral, or fungal infection is an absolute contraindication until it has resolved.

This includes active herpes lesions, impetigo, folliculitis, cellulitis, and clinically significant fungal infection. Ablation can spread infection, delay healing, and increase the risk of scarring.

A history of HSV without active lesions is not usually an absolute contraindication. It is a relative risk requiring antiviral prophylaxis.

Significant connective-tissue disease

The primary screening standard identifies systemic lupus erythematosus and scleroderma as absolute contraindications for ablative resurfacing.

These disorders can impair repair, alter inflammatory responses, and reduce the skin structures needed for re-epithelialization. Patients with suspected, active, or poorly controlled disease should not be treated electively without appropriate specialist evaluation.

Active keloid formation

Active keloid formation or uncontrolled hypertrophic scarring is an absolute contraindication to resurfacing over the affected area.

Thermal injury may stimulate further abnormal collagen deposition. A remote history of a single hypertrophic scar is different from active or widespread keloid disease and is generally handled as a relative contraindication with careful counseling and conservative treatment.

Recent systemic isotretinoin use

The primary reference specifies oral isotretinoin within the preceding 12 months as an absolute exclusion because impaired sebaceous and appendageal function may compromise re-epithelialization.

The literature and device policies vary, particularly for fractional rather than deep full-field treatment. Some protocols use a shorter interval, such as six months, while deeper or more aggressive treatments may warrant a longer delay.

Clinics should therefore document the last dose and follow the more conservative interval required by the device labeling, medical director, and local standard of care. Current isotretinoin use should be treated as a clear reason to defer elective ablative resurfacing.

Inability to comply with aftercare

A patient who refuses or cannot reliably commit to strict post-procedure wound care and approximately six months of sun protection should not undergo treatment.

Ultraviolet exposure substantially increases the risk of persistent erythema and post-inflammatory hyperpigmentation. Failure to cleanse, moisturize, use prescribed medications, avoid picking, or attend follow-up can also convert a controlled injury into infection or scarring.

Unrealistic expectations or psychological unreadiness

Patients expecting flawless skin, immediate results, no downtime, or elimination of all scars are not appropriate candidates until expectations are corrected.

This is not merely a communication issue. Inability to understand the healing course, risks, limitations, or required aftercare makes the procedure unsafe in practice.

Relative Contraindications Requiring Risk Reduction

History of herpes simplex virus

A prior HSV outbreak is a relative contraindication, not necessarily a reason to deny treatment.

For perioral, facial, or extensive resurfacing, clinicians commonly prescribe an oral antiviral such as acyclovir or valacyclovir beginning approximately 48–72 hours before treatment and continuing according to the practice protocol, often through re-epithelialization.

Active HSV lesions, however, require postponement until fully resolved.

Active acne or inflammatory skin disease

Active acne, folliculitis, dermatitis, psoriasis, vitiligo, or another inflammatory eruption in the treatment area increases the risk of worsening inflammation, infection, or abnormal pigment.

Treatment should generally be delayed until the condition is controlled. Where treatment is still considered, use conservative settings and avoid actively inflamed areas.

History of post-inflammatory hyperpigmentation or dyschromia

A prior history of PIH, hypopigmentation, or prolonged erythema indicates increased pigment risk after both CO₂ and Er:YAG resurfacing.

Risk reduction may include conservative density and energy, staged sessions, meticulous photoprotection, appropriate pre- and post-treatment pigment management, and a small test patch. The primary reference recommends considering a localized 2 × 2 cm test area for patients with relative contraindications.

Darker skin phototypes

Fitzpatrick IV–VI skin types are not automatically excluded from fractional resurfacing, but they carry a higher risk of prolonged or permanent dyschromia.

Fractional treatment, lower fluence, reduced density, and test spots are generally safer than aggressive full-field ablation. The treatment plan should be individualized rather than based solely on skin color.

Smoking and nicotine exposure

Smoking can impair oxygen delivery, microvascular function, and wound healing.

Clinics should document smoking status and counsel cessation before and after treatment. Heavy or ongoing smoking may justify postponement, particularly for aggressive ablative procedures or patients with other healing risks.

Diabetes and impaired microvascular healing

Diabetes is a relative contraindication because hyperglycemia and microvascular disease can delay epithelial repair and increase infection risk.

Treatment should be deferred when diabetes is poorly controlled. The clinician should also consider neuropathy, vascular disease, immune status, and the patient’s ability to perform wound care.

Pregnancy and breastfeeding

Pregnancy and breastfeeding generally warrant deferral of elective resurfacing because safety data are limited and treatment may involve topical or systemic medications whose use requires additional review.

If treatment is being considered, the clinician should perform a documented risk–benefit assessment and coordinate with the patient’s obstetric or primary physician. Elective treatment is usually not urgent enough to justify avoidable uncertainty.

Photosensitizing disease or medication

Photosensitivity from collagen-vascular disease or medications can increase the risk of exaggerated inflammation and pigmentary complications.

Review prescription drugs, over-the-counter products, and supplements. Treatment may need to be postponed until the photosensitizing agent is stopped or the underlying condition is evaluated.

Prior radiation or loss of skin appendages

Previously irradiated skin, burn scars, or areas with damaged or absent hair follicles and sebaceous glands may have reduced regenerative capacity.

This is especially important for deep or dense treatment. Depending on the extent and treatment depth, the area may be unsuitable for treatment or may require specialist evaluation, conservative parameters, and a test patch.

Recent deep procedures

Recent deep chemical peels, dermabrasion, deep laser resurfacing, or extensive electrolysis may have already injured or destroyed appendageal structures.

Clinicians should allow adequate recovery and avoid stacking procedures before the skin has fully healed. If treatment proceeds, use a conservative protocol and consider testing a small area first.

Periorbital anatomy and eyelid laxity

For treatment near the eyelids, significant lid laxity, prior blepharoplasty, or pre-existing eyelid malposition increases the risk of contraction-related ectropion.

Periorbital resurfacing requires careful examination of lid support and conservative treatment planning. Patients with meaningful baseline laxity may require oculoplastic assessment or should avoid aggressive treatment in that region.

Understanding the Trade-offs

“Fractional” does not mean risk-free

Fractional delivery reduces the total area injured, but it does not eliminate infection, scarring, pigmentary change, or delayed healing.

Higher density, repeated passes, greater fluence, and treatment over compromised skin can make a fractional procedure behave more like a substantial ablative injury.

Contraindication categories depend on treatment intensity

A history of isotretinoin, darker phototype, or prior dermabrasion may be unacceptable for deep full-field resurfacing but potentially manageable for low-density fractional treatment.

Clinics should avoid using a single universal checklist without recording the intended wavelength, pulse parameters, density, number of passes, anatomic site, and whether the treatment is ablative or non-ablative.

Test patches reduce uncertainty but do not guarantee safety

A 2 × 2 cm test patch can help assess pigmentary response and healing in selected relative-risk patients.

It cannot reliably predict every complication, particularly delayed scarring, infection, or the effect of treating a much larger surface area. A reassuring test result does not override an absolute contraindication.

Conservative settings are not a substitute for informed consent

Risk modification may reduce complications, but it does not remove them.

Patients should understand expected downtime, temporary erythema, pigment changes, infection risk, possible scarring, the need for antiviral prophylaxis when indicated, and the possibility of incomplete or uneven improvement.

How to Apply This to Your Screening Protocol

Use a two-stage process: first identify conditions that require deferral, then determine whether relative risks can be reduced sufficiently for treatment.

If your primary focus is patient safety: Defer treatment for active infection, significant lupus or scleroderma, active keloid formation, recent systemic isotretinoin under your documented policy, or inability to follow wound care and sun protection.
If your primary focus is minimizing pigment complications: Assess phototype and prior PIH, use conservative fractional parameters, optimize photoprotection, and consider a 2 × 2 cm test patch.
If your primary focus is preventing HSV reactivation: Treat a prior HSV history as a relative contraindication and arrange appropriate antiviral prophylaxis; postpone treatment for active lesions.
If your primary focus is reliable wound healing: Address diabetes control, smoking, immune status, prior radiation or deep procedures, and the condition of the skin appendages before selecting treatment parameters.
If your primary focus is periorbital treatment: Examine lid laxity and prior eyelid surgery before treating near the eyes, and obtain specialist input when contraction could cause ectropion.
If your primary focus is regulatory and clinical consistency: Record the device type, treatment depth, isotretinoin interval, contraindication decision, counseling, prophylaxis, and follow-up plan for every patient.

A disciplined screening process makes fractional resurfacing safer by matching the treatment intensity to the patient’s ability to heal, protect, and follow through.

Summary Table:

Contraindication Type	Condition	Action
Absolute	Active infection	Defer treatment until resolved
Absolute	Significant connective tissue disease (e.g., lupus, scleroderma)	Do not treat electively
Absolute	Active keloid formation	Do not treat affected area
Absolute	Recent systemic isotretinoin use (within 12 months or per policy)	Defer treatment
Absolute	Inability to comply with aftercare	Do not treat
Relative	HSV history	Provide antiviral prophylaxis
Relative	Darker skin types (IV-VI)	Use conservative settings, consider test patch
Relative	Smoking	Counsel cessation, consider postponement
Relative	Diabetes	Ensure control, delay if poorly controlled
Relative	Pregnancy/Breastfeeding	Defer elective treatment
Relative	Prior radiation or deep procedures	Evaluate healing capacity, use conservative parameters
Relative	Periorbital laxity	Obtain oculoplastic assessment if needed

Ensure your clinic's safety protocols meet the highest standards. BELIS offers a full range of professional-grade aesthetic lasers, including Er:YAG and CO2 fractional systems, designed for clinics and premium salons. Our expertise and advanced technology can help you deliver exceptional results while prioritizing patient safety. Contact us today to learn how our solutions can enhance your practice.